Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback